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Background: To evaluate the impact of oral health on the quality of life (QOL) of individuals undergoing cancer 
treatment at the time of diagnosis of medication-related osteonecrosis of the jaw (MRONJ). 
Material and Methods: The present cross-sectional study analyzed patients with MRONJ from 2013 to 2019. The 
collected data included demographic data, base disease, medications associated with MRONJ, route of administra-
tion and time of use, signs, symptoms, and tomographic features of acute MRONJ, staging according to American 
Association of Oral and maxillofacial Surgeons position paper 2014 (AAOMS), type of dental treatment perfor-
med, outcome, and the responses to the Oral Health Impact Profile questionnaire (OHIP-14). Statistical analysis 
was performed using the Tukey test to study the association between oral condition and the QOL. A p-value of less 
than 0.05 was considered statistically significant. 
Results: The sample consisted of 16 medical records of patients with MRONJ. Psychological discomfort showed 
alarmingly significant results (p < 0.001) with strong negative impact on the QOL of the patients. Functional limita-
tion was the least affected dimension (p = 0.747). The other dimensions did not show statistically significant results. 
Conclusions: MRONJ compromises oral health and negatively impacts the QOL, especially with respect to the 
psychological discomfort (worry and stress). The OHIP-14 questionnaire proved to be an effective tool in the as-
sessment of this impact.
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Introduction
Medication-related osteonecrosis of the jaw (MRONJ) 
is associated with symptoms, such as halitosis, severe 
pain, difficulty in chewing, and dysphagia, that have a 
negative impact on the quality of life (QOL) (1,2). The 
QOL indicators are related to physical, social, and psy-
chological well-being and can be assessed through ge-
neric or specific questionnaires according to the type of 
disease (3).
The Oral Health Impact Profile questionnaire (OHIP-14) 
(4) has been widely used (5,6) and allows the self-as-
sessment of the individual with respect to the impact of 
oral health on the QOL. The OHIP-14 is a questionnai-
re recognized for its sensitive potential for interference 
in the QOL. It is a low-cost, easily applied tool, and it 
allows a greater access to the population. Consequently, 
it helps in identifying the effects on the QOL of indivi-
duals, enabling the best targeted treatment. Though stu-
dies have reported a high prevalence of MRONJ (7,8), 
very few have reported its impact on the QOL (5,9,10). 
According to the SF-12 questionnaire that evaluates the 
general QOL (2), MRONJ is a condition that can lead to 
worsening of the physical and mental state of patients. 
Treatment for MRONJ aims to restore the QOL by resol-
ving the symptoms in the jaws (11).  
Researchers have pointed out the scarcity in the litera-
ture about oral health impairment and the QOL of can-
cer patients (10,13-16). A high incidence of suicides has 
been demonstrated in cancer patients, probably due to 
the functional alterations that drastically affect the QOL 
(17). Therefore, the importance of preserving the QOL 
of these individuals through prevention and control of 
MRONJ (2,5,16) becomes crucial.
The aim of this study was to evaluate the impact of oral 
health on the QOL in individuals undergoing cancer 
treatment at the time of diagnosis of MRONJ.
Material and Methods
The present cross-sectional study was conducted at a 
clinical research center specializing in care for systemi-
cally compromised individuals through the analysis of 
902 medical records of patients who underwent dental 
treatment from 2013 to 2019. Sixteen medical records 
of patients with MRONJ were selected. This study was 
approved by the Research Ethics Committee of the Uni-
versity of São Paulo (CAAE: 65053617.0.0000.5417).  
Demographic data collected from the 16 medical records 
included name, gender, age, base disease, medications 
associated with MRONJ, route of administration and 
time of use, signs, symptoms, and tomographic featu-
res of acute MRONJ, staging according to the norms by 
AAOMS (1), type of dental treatment performed, outco-
me of MRONJ, and impact of oral health on the QOL.
The portuguese version (18) of the OHIP-14 was used 
as the QOL questionnaire in which 7 dimensions were 
divided into 14 questions with responses attributed by 
the individuals through a Likert scale (0 to 4) to quantify 
the impact of oral health on the QOL. The value of the 
answers was multiplied by the power corresponding to 
each question to calculate the total value for each di-
mension. 
The seven dimensions included functional limitation, 
physical pain, psychological discomfort, physical disa-
bility, psychological disability, social disability, and 
disability. Values for each dimension were calculated 
and the impact of each dimension was classified as low 
(0 - 1.33), medium (1.33 - 2.68), or high (> 2.68). Ac-
cording to the total values the correlation was classified 
as having weak impact (< 9.33), medium impact (9.33-
18.66), or strong impact (> 18.66). Higher values sug-
gested greater negative impact of oral health on the QOL 
of the patients. Statistical analysis of the obtained data 
was performed using the Tukey test to study the correla-
tion between oral condition and the QOL. Results were 
considered statistically significant when the p-value was 
less than 0.05.
Results
Tables 1, 2, and 3 show the demographic data and the 
base diseases or metastases, the clinical / imaging cha-
racteristics of patients with MRONJ, and the characte-
ristics related to osteonecrosis-associated drugs.
The dimension related to psychological discomfort 
(D3), which evaluated the degree of concern and stress, 
showed the most significant (p < 0.001) strong negative 
impact on the QOL of the individuals under study. The 
dimension related to functional limitation (D1), which 
assessed the impact on word pronunciation and dysgeu-
sia, showed the least impact (p = 0.747) on the QOL. No 
significant results were observed for the other dimen-
sions (p > 0.05). The values obtained from the OHIP-14 
according to the dimensions are listed in table 4.
Discussion
Demographic factors such as age, gender, and location 
of the neoplasm may interfere with the development of 
MRONJ. In the present study, 9 (56.25%) cases were 
female. The relatively higher incidence of the disease 
in females may be due to a higher frequency of diseases 
such as breast cancer and osteoporosis in women (1), and 
subsequently, greater indication of the drugs that may be 
responsible for MRONJ. Mandible was the most affec-
ted region (10 [62.5%] cases) followed by the maxilla 
(6 [37.5%] cases). These findings can be explained by 
the local vascular characteristics. Since the mandible 
has less vascularization when compared with the maxi-
lla (16), the incidence of osteonecrosis may be higher.
The OHIP-14(18) questionnaires were applied at the 
time of the diagnosis of MRONJ. The responses showed 
alarming negative results for the dimension of psycho-
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Gender Female: 9 (56,25%)
Male: 7 (43,75%)




Base Disease (location) Breast: 8 (50%)
Renal: 3 (18,75%)
Prostate: 3 (18,75%)
Multiple Myeloma: 1 (6,25%)
Straight: 1 (6,25%)





Location Maxila: 6 (37,5%)
Mandible: 10 (62,5%)




No clinical sign: 1 (3,33%)
Not reported: 3 cases
Imaging characteristics (MRONJ sites) Nonhealing extraction sockets: 9 (60%)
Irregular borders: 2 (13,33%)
Suggested bone sequestration: 2 (13,33%)
Bone esclerosis: 1 (6,67%)
No change: 1 (6,67%)
Not reported: 4 cases
Imaging characteristics (sites without clinical 
signs of MRONJ)
Bon esclerosis: 6 (31,58%)
Nonhealing exraction sockets: 4 (21,05%)
Increased periodontal ligament space: 3 (15,80%)
Lamina dura thickening: 2 (10,53%)
Buco-sinus communication: 1 (5,26%)
Cortical irregularities: 1 (5,26%)
Bone trabecular hypodensity: 1 (5,26%)
Hyperdensity around implant: 1 (5,26%)
Nor reported: 4 cases




Table 1: Demographic data (age, sex, type / location of cancer, and occur-
rence of metastasis).
Table 2: Clinical and imaging characteristics of patients with MRONJ.
†MRONJ: Medication-related osteonecrosis of the jaw
‡AAOMS: American Association of Oral and Maxillofacial Surgeons 
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Zoledronic acid + Pamidronate: 1 (6,25%)
Route of administration Intravenous: 14 (87,5%)
Oral: 2 (12,5)
Usage time (months) Minimum: 6
Medium: 36
Maximum: 108
Table 3: Types of MRONJ†-associated drugs.
† MRONJ: Medication-related osteonecrosis of the jaw
Total D1/LF D2/PP D3/PD* D4/PD D5/PD D6/SD D7/D
19.86 1.47 4 4 1.56 3 2.24 3.59
9.91 1.96 1.66 3.55 1.56 0 0 1.18
1.24 0 0.34 0.9 0 0 0 0
6.05 0.98 1.66 1.1 0.96 0 0.76 0.59
7.7 0 0.68 0.9 1.48 1.6 1.86 1.18
15.67 0.98 2.68 3.1 2.52 1.8 2 2.59
14.1 0.51 2.98 4 1.56 2.2 0.62 2.23
14.48 2.98 1.98 4 1.04 0 2.48 2
17.41 1.47 2.66 4 2.08 1.6 3.24 2.36
9.32 0.98 1.32 4 1.04 0.8 0 1.18
3.83 0 0.34 1.45 0 0.8 1.24 0
11.22 0.49 1.32 2.9 0.52 1.6 2.62 1.77
22.35 1.96 4 4 3.52 2.8 2.48 3.59
9.92 0.98 1.98 1.8 0.48 2.2 2.48 0
0.68 0 0.68 0 0 0 0 0
18.17 0 3.34 3.1 2.52 2.8 3 3.41
Table 4: Results after application of the OHIP-14† questionnaire according to the total value and the 7 dimensions.
*Statistically significant (P < 0.05) 
†The Oral Health Impact Profile questionnaire
D1 to D7: Dimensions, LF: Functional Limitation, PP: Physical pain, D3/PD: psychological discomfort, D4/PD: physical disability, 
D5/PD: psychological disability, SD: social disability, D: Disability
logical discomfort in which the highest score regarding 
oral health concerns and stress was observed. After com-
parison among the dimensions of functional limitation 
(D1), physical pain (D2), and psychological discomfort 
(D3), highest scores were seen for D3 followed by D2. 
The scores for the dimension D1 were the lowest when 
compared with all the other dimensions.
A recent study showed that the most affected dimen-
sions were functional limitation (D1), physical pain 
(D2), and physical disability (D4). These findings are 
different from results of the present study. OHIP-14 can 
be applied at different stages including before, during, 
and after the cancer treatment. This approach allows the 
comparisons among various stages and may directly in-
terfere with the results. Another study emphasized that 
psychological discomfort (D3) is generated by the high 
level of anxiety and acute pain in patients with MRONJ 
(19). Since the present study was a cross-sectional study, 
OHIP-14 was applied only after the presence of MRONJ 
was confirmed. This may be a limitation of the present 
study, since comparisons during the other stages in the 
same patients was not possible.
The imaging characteristics of MRONJ are more fre-
quently observed in the more advanced stages where it 
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is possible to observe changes such as a larger area of 
bone involvement, painful symptoms, and neurosensiti-
ve alterations, which result in alterations in chewing and 
swallowing and significant deterioration in the QOL. 
(20,21) 
The stagewise classification facilitates the diagnosis and 
the therapeutic management of MRONJ (1). Among the 
4 classification stages (0, I, II, III), stage I was the most 
prevalent in the present study, followed by stage II and 
stage 0. Stage III was not observed. The treatment of 
MRONJ aims to reduce the painful symptoms, control 
infection, and reestablish social contact with family and 
friends, thus improving the physical and mental state 
and consequently improving the QOL of these indivi-
duals (11,22).
QOL was negatively affected by psychological discom-
fort in our study with a strong correlation (p < 0.001), 
which we highlight as a differential (5,23). Since con-
cern and stress is associated with patients’ oral health 
and osteonecrosis symptoms, it is important to develop a 
multidisciplinary treatment approach with medical, den-
tal, and psychological support to minimize the impact of 
MRONJ on the QOL. 
The best way to assess the impact of oral health on the 
QOL would be to apply the OHIP-14 before and after 
the MRONJ treatment and compare the results. This 
approach was not possible in the present study, as some 
patients died due to disease complications.
The results of the present study showed that MRONJ ne-
gatively affects the oral health of the patients, especially 
with respect to psychological discomfort. The OHIP-14 
proved to be an effective tool in assessing the impact of 
oral problems on the QOL.
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